Technology
Since Kingsley CS introduced the concept of Platelet-Rich Plasma (PRP) in 1954, and M. Ferrari et al. reported its autologous blood transfusion application in cardiac surgery in 1987, high-concentration platelet therapy has accumulated over 50 years of clinical history. More than 5,200 studies have explored its applications across diverse medical fields, including orthopedics, sports medicine, dentistry, ENT, neurosurgery, ophthalmology, urology, wound healing, aesthetic medicine, cardiac and thoracic surgery, and oral/maxillofacial surgery.
However, treatments using conventional PRP require immediate administration after separation and cannot be stored long-term. As a result, patients must endure repeated blood draws before each treatment. Furthermore, platelet concentration in PRP varies depending on the patient’s health at the time of blood collection and the centrifugation method used. Clinicians cannot immediately measure platelet count or active component levels during treatment, making therapeutic outcomes highly variable, a common concern for physicians using PRP.
To address these limitations, Spirit Scientific developed a platelet lyophilization process (patent no. I480066). Using pharmaceutical-grade, precise dosing principles, platelets are isolated at defined concentrations, purified, and stabilized. High-concentration platelets are then vacuum freeze-dried, removing water and impurities to produce a long-term storable PLT (Platelet Lyophilized Treatment) product.
Spirit Scientific’s patented technology precisely defines the platelet content obtained through purification and separation, with one billion platelets per vial. Each batch of lyophilized product undergoes Enzyme-Linked ImmunoSorbent Assay (ELISA) to measure active platelet concentration, eliminating variability caused by individual differences in autologous platelets. Clinicians using Spirit Scientific’s PLT high-concentration autologous platelet lyophilized treatment can accurately know the total platelet dose and activity, enabling estimation of treatment efficacy and planning of precise therapeutic schedules.
After freeze-drying, platelets are thoroughly dehydrated and vacuum-sealed. In-house real-time storage testing confirms that the product is highly stable and can be stored at room temperature for over three years. Patients can therefore receive treatment directly in the clinic at any time during the product’s shelf life, without repeated blood draws. Reconstitution in the clinic takes less than 10 seconds, offering maximum convenience for medical staff and patients.
Precise Dosing
1 billion platelets per vial, allowing flexible use.
Convenient Treatment
Single blood draw enables multiple therapy sessions.
Patented Activation Technology
High product stability ensures consistent therapeutic efficacy.
Innovative Multi-Application
Applicable across specialties and various indications.
Safety Assured
Derived from autologous blood, eliminating allergic or rejection risks.
Exclusive Lyophilized Technology
Maintains platelet activity at room temperature for three years.
Spirit Scientific`s Patents
JP7527536(日本) / US12059495(美國)
